Achaogen Stock

AKAOQ

US0044491043

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

12/06/20	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/05/20	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Employees

Sector

More about the company

Market Cap	639K 550K 521K 472K 886K 61.03M 891K 6.19M 2.38M 31.05M 2.4M 2.35M 98.11M	P/E 2017	-3.39x	P/E 2018	-0.29x
Enterprise Value	19.47M 16.77M 15.88M 14.39M 27.01M 1.86B 27.14M 189M 72.53M 946M 73.11M 71.51M 2.99B	EV / Sales 2017	28x	EV / Sales 2018	8.66x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

12/06/20	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/05/20	Achaogen, Inc. Went Out of Business	CI
29/05/20	First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	CI
22/04/20	First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
21/04/20	Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	CI
30/03/20	Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
09/01/20	Motion for Asset Sale Approved for Achaogen, Inc.	CI
29/12/19	Motion for Asset Sale Filed by Achaogen, Inc.	CI
24/09/19	Final DIP Financing Approved for Achaogen, Inc.	CI
29/08/19	Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	CI
13/08/19	First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	CI
30/07/19	Achaogen, Inc. Announces Management Changes	CI
23/07/19	Motion for Asset Sale Approved for Achaogen, Inc.	CI

	2017	2018
Net sales	11.18M 9.63M 9.12M 8.26M 15.5M 1.07B 15.58M 108M 41.64M 543M 41.97M 41.05M 1.72B	8.73M 7.52M 7.12M 6.45M 12.11M 834M 12.17M 84.57M 32.52M 424M 32.78M 32.06M 1.34B
Net income	-126M -108M -102M -92.89M -174M -12B -175M -1.22B -468M -6.11B -472M -461M -19.29B	-187M -161M -152M -138M -259M -17.82B -260M -1.81B -695M -9.07B -700M -685M -28.65B
Net Debt	-143M -123M -117M -106M -198M -13.65B -199M -1.38B -532M -6.94B -536M -525M -21.94B	18.83M 16.22M 15.36M 13.92M 26.12M 1.8B 26.25M 182M 70.15M 915M 70.71M 69.16M 2.89B

Achaogen Stock

Stocks

AKAOQ

US0044491043

Valuation : Achaogen

Latest news : Achaogen

Financials

Company Profile